Get the Stockscreener App
42.09
3.21%
-1.40
Crispr Therapeutics Ag stock is traded at $42.09, with a volume of 364.48K.
It is down -3.21% in the last 24 hours and down -3.21% over the past month.
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$43.49
Open:
$43.2
24h Volume:
364.48K
Relative Volume:
0.18
Market Cap:
$3.69B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-15.03
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-2.81%
1M Performance:
-3.21%
6M Performance:
-13.99%
1Y Performance:
-43.71%
1-Day Range:
$42.02
$44.39
1-Week Range:
$40.82
$46.07
52-Week Range:
$36.52
$75.91
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
42.07 | 3.69B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.55 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.94 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Gene Editing Market Future Business Opportunities 2025-2032 | - openPR
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Crispr Therapeutics CEO sells shares worth $616,348 By Investing.com - Investing.com South Africa
Crispr Therapeutics general counsel sells shares worth $169,242 By Investing.com - Investing.com South Africa
Crispr Therapeutics general counsel sells shares worth $169,242 - Investing.com India
Crispr therapeutics COO Bruno Julianne sells $59,049 in common shares - Investing.com India
Crispr therapeutics COO Bruno Julianne sells $59,049 in common shares By Investing.com - Investing.com Australia
Crispr Therapeutics CEO sells shares worth $616,348 - Investing.com
CRISPR Therapeutics AG Executives Sell Shares - TradingView
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 0.9%Here's What Happened - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 3.9%Time to Sell? - MarketBeat
Jones Financial Companies Lllp Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Oppenheimer & Co. Inc. Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3%Time to Sell? - MarketBeat
If I Could Buy Only 1 Growth Stock, This Would Be It - The Motley Fool
Brokers Issue Forecasts for CRSP FY2027 Earnings - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading 0.9% HigherHere's What Happened - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 1.9%Here's Why - MarketBeat
Vestmark Advisory Solutions Inc. Purchases 69,937 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Zacks Research Has Bullish Forecast for CRSP Q2 Earnings - MarketBeat
SBI Securities Co. Ltd. Invests $281,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
When (CRSP) Moves Investors should Listen - Stock Traders Daily
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.9%Time to Sell? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.7%Here's What Happened - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Oppenheimer & Co. Inc. - Defense World
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.5%Time to Sell? - MarketBeat
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Q2 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - Defense World
CRISPR Therapeutics validates InvestingPro’s overvaluation warning By Investing.com - Investing.com
Shareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested a year ago - Yahoo Finance
FY2027 Earnings Forecast for CRSP Issued By Zacks Research - MarketBeat
Insider Buying: CRISPR Therapeutics AG (NASDAQ:CRSP) Director Purchases 7,000 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading 4.7% HigherHere's Why - MarketBeat
John Greene Purchases 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 1.2% After Insider Buying Activity - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Trading 2.5% HigherStill a Buy? - MarketBeat
Leerink Partnrs Issues Positive Forecast for CRSP Earnings - MarketBeat
Top 5 CRISPR Companies To Invest In (March 2025) - Securities.io
ARK Investment Management LLC Buys 1,474,439 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr therapeutics director John Greene buys $313,947 in common shares By Investing.com - Investing.com South Africa
Prediction: CRISPR Therapeutics Will Beat The Market. Here's Why - Barchart
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):